Skip to main content
Journal cover image

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Publication ,  Journal Article
Zeidan, AM; Lee, J-W; Prebet, T; Greenberg, P; Sun, Z; Juckett, M; Smith, MR; Paietta, E; Gabrilove, J; Erba, HP; Tallman, MS; Gore, SD ...
Published in: Br J Haematol
August 2014

The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

Duke Scholars

Published In

Br J Haematol

DOI

EISSN

1365-2141

Publication Date

August 2014

Volume

166

Issue

3

Start / End Page

352 / 359

Location

England

Related Subject Headings

  • Treatment Outcome
  • Prognosis
  • Myelodysplastic Syndromes
  • Immunology
  • Humans
  • Histone Deacetylase Inhibitors
  • Azacitidine
  • Antineoplastic Combined Chemotherapy Protocols
  • Antimetabolites, Antineoplastic
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zeidan, A. M., Lee, J.-W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., … Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup, . (2014). Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol, 166(3), 352–359. https://doi.org/10.1111/bjh.12884
Zeidan, Amer M., Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, et al. “Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.Br J Haematol 166, no. 3 (August 2014): 352–59. https://doi.org/10.1111/bjh.12884.
Zeidan AM, Lee J-W, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Tallman MS, Gore SD, Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol. 2014 Aug;166(3):352–359.
Journal cover image

Published In

Br J Haematol

DOI

EISSN

1365-2141

Publication Date

August 2014

Volume

166

Issue

3

Start / End Page

352 / 359

Location

England

Related Subject Headings

  • Treatment Outcome
  • Prognosis
  • Myelodysplastic Syndromes
  • Immunology
  • Humans
  • Histone Deacetylase Inhibitors
  • Azacitidine
  • Antineoplastic Combined Chemotherapy Protocols
  • Antimetabolites, Antineoplastic
  • 3201 Cardiovascular medicine and haematology